The current chemotherapies are often associated with significant morbidity and enhanced toxic side effects.
For the ease of application, enhanced stability, decreased side effects, enhanced patient compliance, and the ease of discontinuation on desire, there have been a lot of efforts to deliver ACE by topical route [ 35– 35].
The persistent use of OTC NSAIDs in the older population is an area of concern, given the enhanced risk of side effects and increased incidence of comorbidities.
Advantages of the conjugates over treatment with drugs alone, demonstrated by clinical trials, include fewer side effects, enhanced therapeutic efficacy, and improved patient compliance.
A variety of nanocarrier (NC) systems in early cancer therapeutic clinical results showed enhanced efficacy and reduced side effects [ 18– 27].
As a cancer treatment regimen, relatively high drug concentration in tumor tissue compared to non-target tissues is advantageous for many reasons, including enhanced efficacy and reduced side effects.
To address this problem, attention has been focused on finding a novel combination of anticancer agents with nonoverlapping mechanisms of action to achieve enhanced efficacy with decreased side effects.
However, in clinical trials on head and neck cancer using MMC, only little or no evidence of enhanced mucosal or dermal side effects was found, whereas locoregional tumour control was considerably increased (Haffty et al, 1997; Dobrowsky and Naude, 2000; Budach et al, 2001).
From the chemical structures of HIV protease inhibitors and their possible off-target molecules, we could obtain hints for optimizing the molecular selectivity of the inhibitors, to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.
Our novel strategy would have profound implications in both enhanced chemotherapy efficacy and minimized side effects.
